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Abstract
What is the value of an early (presymptomatic) diagnosis of dementia in the absence of effective treatment? There has been a 
lively scholarly debate over this question, but until now (future) patients have not played a large role in it. Our study supple-
ments biomedical research into innovative diagnostics with an exlporation of its meanings and values according to (future) 
patients. Based on seven focusgroups with (future) patients and their care-givers, we conclude that stakeholders evaluate 
early diagnostics with respect to whether and how they expect it to empower their capacity to (self-) care. They value it, for 
instance, with respect to whether it (a) explains experienced complaints, (b) allows to start a process of psychological accept-
ance and social adaptation to the expected degeneration, (c) contributes to dealing with anxieties (with respect to inheritable 
versions of dementia), (d) informs adequately about when to start preparing for the end of life, (d) informs the planning of 
a request for euthanasia, or (e) allows society to deal with a growing amount of dementia patients. Our study suggests that 
information about disease is considered ‘harmful’ or ‘premature’ when recipients feel unable to act on that information in 
their (self-) care. The results of this research offers input to further ethical research. It invites to adopt a care perspective in 
evaluation and to seek ways to prevent the ‘harm’ that such diagnostic methods can bring about.
Keywords Early diagnostics · Dementia · Ethics · Stakeholder discussion · Care · Cure
Introduction
The rapidly aging population and the rising prevalence of 
dementia in society is causing many societal concerns, to 
which diverse academic fields seek an appropriate response 
(Winblad et al. 2016). As the gradual cognitive degeneration 
of patients with dementia has an enormous impact on the 
lives of these patients and their relatives, as well as on soci-
ety, scientists have engaged in various investigations in order 
to find an appropriate response to it. Neurochemical research 
into biomarkers that indicate early stage dementia—or which 
are able to predict dementia pre-symptomatically—is one 
example of such scientific investigations. Such neurochemi-
cal biomarkers, usually quantified in cerebrospinal fluid 
(CSF), support to define a diagnosis that is expected to dif-
ferentiate between different types of dementia in patients 
during life (as opposed to post mortem examination) and it 
may offer a useful quantitative scale to monitor the effects 
of experimental pharmacological treatment during a clinical 
trial. Yet, early (presymptomatic) diagnostics of Alzheimer 
and other types of dementia also raises ethical debate; for 
what is the value of having a (predictive) diagnosis, espe-
cially when it is unsure whether effective treatment will 
become available? What are the the harms and benefits for 
the lives of patients when this diagnosis is communicated 
to patients?
There is debate about this question in the social sciences 
and in ethics. Many scholars in these fields regard dementia 
biomarker research with reserve (Jongsma and Sand 2017; 
Cuijpers and Van Lente 2015; Innes and Manthorpe 2013; 
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Peine et al. 2015; Boenink et al. 2011; Van der Laan and 
Olthuis 2013). Some criticize it for offering reduction-
ist ideas about what dementia is and ‘how we might try to 
respond to or look for a solution’ to it (Innes and Manthorpe 
2013). Others state that biomarker research presupposes that 
dementia is a disease with a biochemical source, while it 
could just as well be understood quite differently as a set of 
functional problems or part of normal aging (Moser 2008, 
2011). It matters, according to these scholars, how dementia 
is understood, as these understandings invite different kinds 
of responses. Looking for a cure (a so-called ‘technological 
fix’) would make sense if dementia is understood as a dis-
ease with a biochemical source. However, some argue that 
dementia also needs to be approached in a broader way as 
history points out that the hope to find a cure often fails to 
materialize, or materializes in a sub-optimal manner, such 
as is the case with promises to provide a ‘cure for cancer’ 
(Jongsma and Sand 2017). The focus on finding a cure for 
dementia should therefore not eclipse attention for more low 
tech ‘caring’ responses that dementia patients should be able 
to fall back on—and which represent, according to some, a 
much better strategy to deal with dementia (Cuijpers and 
Van Lente 2015).
This scholarly debate has been taking place over some 
time now. But it is not very clear yet, how (future) patients 
would value having a (predictive) test. Interest in the per-
spectives of patients on biomedical research is growing in 
the past years (Van der Scheer et al. 2014). It has been pro-
moted for different reasons: such as, for the democratization 
of science (Nowotny 2003), to improve alignment of bio-
medical innovation with the wishes of patients as the con-
sumers of health care services (Boote et al. 2006), to make 
the biomedical research agenda responsive to the needs of 
patients (Abma and Broerse 2010), or to improve the quality 
of biomedical research by means of a coupling of patient’s 
experiential knowledge with the disease to the biomedical 
knowledge of scientists (Caron-Flinterman et al. 2005). In 
the domain of research into Alzheimer’s diagnostics, not a 
lot of research into patient perspectives have been done until 
now. While several authors have recommended organizing 
stakeholder engagement dialogues to anticipate the socio-
cultural meanings attached to early (presymptomatic) Alz-
heimer’s diagnostics and assess its value for patients, there 
have until now been little attempts to actually do so (Peine 
et al. 2015; Boenink et al. 2011). As interesting exception, 
a recent study compared care and cure-oriented meanings 
attached to Alzheimer used in health technology assessment 
with the interpretations provided by patients and their care-
givers in Alzheimer cafés (Cuijpers and Van Lente 2015). 
This work was, however, conceptual and did not actually 
offer an assessment of the value of biomarker diagnostics 
for the future lives of patients.
In our research, we aimed to fill this gap. Our goal was 
to provide insight into what the meaning is of biomarker 
diagnostics in the lives of (future) patients, and whether and 
how they value the various possible roles that it can play in 
their lives. This is an empirical exploration. Yet, we think 
it can offer valuable input to ethical reflection. As ethics of 
the ‘good life’ enquires into what the good life is, and what 
it means to live well, it seems appropriate to explore whether 
and how people with a disease such as dementia, value an 
innovative method that allows to set their diagnosis early and 
if it strengthens or weakens their capacity to live a good life. 
This is important empirical input to an ethical assessment of 
the envisioned diagnostic method.
Method
The study we describe in this article was part of a larger 
multi-center research project investigating biomarkers in 
the cerebrospinal fluid CSF indicative of Cerebral Amyloid 
Angiopathy (CAA). The gradual increase of these biomark-
ers is considered explanatory for dementia complaints. CAA 
also increases the risk for intracerebral hemorrhage (ICH), 
which can lead to death or—depending on the location 
where it strikes- to mild to severe disability. Patients who 
survive their ICH are at increased risk for dementia, with 
an incidence of 28% up to 4 years after ICH (Moulin et al. 
2016). Moreover, in CAA patients without ICH, the risk of 
dementia is very high; up to 73% after 5 years of follow-up 
(Xiong et al. 2017).
The multi-center research project aimed to investigate the 
CAA biomarkers. But the project also contained a workpack-
age on ethics and patient involvement, which was carried 
out at the same time. In this workpackage we explored the 
concepts and values that play a role in the viewpoints of end 
users, defined as (future) patients and their care-givers. We 
wanted to find out what the meaning of (predictive) diag-
nostic knowledge is for their lives, and what personal and 
societal values they ascribe to it. This work package started 
out as ‘ethical parallel research’, which supplements research 
into a new technology with an (empirical) ethical investiga-
tion that aims to explore and evaluate its impacts on the lives 
of future users, such as patients (Van der Burg 2009; Van 
Gorp and van der Molen 2011; Van der Burg and Swierstra 
2013; Flipse et al. 2013). The purpose of ‘parallel’ research 
is that it aims to engage end-users in scientific (technologi-
cal) research, anticipate impacts of research and innovative 
technology on human (social) live, and enhance reflection 
about its value among the various stakeholders. In this sense 
it fits with calls for responsible research and innovation (Bur-
get et al. 2016; Guston et al. 2014; von Schomberg 2011). 
At the end of this research, however, the ethical part was no 
longer carried out in parallel, but it became integrated in the 
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project: as the results lead to lively discussions with physi-
cians and chemical neurologists who took part in the project, 
which helped to shape the discussion-part of this article, we 
eventually decided to co-author this article.
Design
As our goal was to explore what meanings and values 
(future) patients and care-givers ascribe to (early) CAA 
diagnostics, we needed to enhance their reflection on some-
thing that they probably did not think about before. Early 
CAA diagnostics is still a topic for research, so chances are 
small that participants in our research encountered it in their 
daily lives and thought about it a lot prior to our research. 
We therefore chose to engage participants in focusgroups, as 
this is a common way to generate reflection and discussion 
about a wide variety of topics, and we used cards to be able 
to give input to their reflective exchange.
Cards are regularly used in qualitative research, and are 
appreciated as a way to engage patients (even illiterate ones) 
in a discussion, especially when they are reluctant to speak 
or are afraid they may have nothing to say about the subject 
(Kitzinger 1994). Cards provide input to reflection and invite 
a response, even when topics are experienced as shameful 
or sensitive (Chang et al. 2005; Sutton et al. 2011). Cards 
are also used in a different domain; namely, to stimulate 
reflection and debate about topics that people do not usu-
ally think about, such as when members of the public are 
asked to reflect on the design of innovative artefacts (Sealea 
et al. 2002), or when laymen in science are demanded to 
explore or assess the value of scientific or technological 
futures (Davies and Macnaghten 2010; Felt et al. 2014; https 
://playd ecide .eu).
As early (presymptomatic) test of CAA is a method that 
the people in our focusgroups likely have little experience 
with, we chose to use a card-game method for our focus-
groups (Boenink et al. 2011; Felt et al. 2014). This card 
game enhances the imagination of participants in a struc-
tured and focused way, about the possible impacts of the 
CAA detection method on their own lives and on society. 
This is done by means of differentsets of cards, which each 
provide input to a round of the conversation. Here we chose 
to do three rounds of conversation and made three sets of 
cards. While the card method has sometimes four stages 
(and four sets of cards) we wanted to limit the needed time-
investment of the participants.
1. First round. The first set of cards present four possible 
future uses of biomarker information for CAA and par-
ticipants were invited to react intuitively.
2. Second round. The second set of cards present personal 
values which invite participants to articulate and reflect 
on the these future uses for their own personal lives.
3. Third round. The third set of cards offer statements or 
opinions related to the value of various future uses for 
society.
In each of the conversation rounds, participants received 
cards with different input for their reflection. But the cards 
function only as a reflection and discussion starter; they do 
in no way determine the course or content of the conversa-
tion. What is specific about our card game, and it has this in 
common with the IMAGINE card game by Felt et al. (2014), 
is that the choice of cards is kept at the level of the individ-
ual. Each participant gets his or her set of cards and chooses 
the cards that are relevant to him or her, and shapes what he 
or she wants to say in the focusgroup in agreement or in con-
trast with these cards. The cards will therefore give input to 
individual reflection, and help to form thoughts about a new 
subject, but participants in the focusgroup are subsequently 
free to do with the cards as they please: so, they can choose 
topics from the cards, or ignore them, or add topics.
To make the cards effective reflection and discussion 
enhancers, we gave them a content specific to this project. 
Based on an exploration of the literature describing the soci-
etal value of (early) diagnostics of dementia, we developed 
an interview guide to conduct interviews (live and by phone) 
with project members and five patient-representatives: two 
members of the HCHWA-D patient organization who have 
an inheritable version of CAA which leads to early onset 
dementia or ICH, two from Alzheimer NL, and one patient 
who suffered a stroke from the Heart Foundation. Based 
on the interviews we identified four possible future uses of 
(presymptomatic) CAA detection in brain fluid (see Box 1), 
which we described in the first set of cards.
Box 1  First set of cards—possible future uses
– For diagnostics: helping to set the diagnosis after patients present 
themselves to a medical doctor with complaints
– For population screening: detecting an early stage of CAA develop-
ment in pre-symptomatic healthy middle aged adults (say, 45 +), 
which implies a risk to develop dementia complaints later in life
– For research: allowing to monitor the effect of experimental medi-
cine on the associated biomarkers in CSF
– For monitoring: keep check of the development of the disease in 
patients in order to know when they can expect their complaints to 
worsen
– Empty card
In addition to future uses, we described a list of personal 
values that came forwards in the interviews (see Box 2) and 
a list of societal dilemma’s (Box 3), based on the literature 
and the interviews. In all sets of cards we added empty cards 
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to allow participants to add additional uses, personal values 
or societal issues that participants in the focusgroups thought 
were missing on the cards.
Box 2  Second set of cards—personal values
Knowledge Care Safety Acceptance
Control Life Medicalization Open future
Autonomy Hope Relationships Empty card
Box 3  Societal issues
• Costs should not play a role in the selection of a diagnostic method 
for CAA 
• Society should primarily invest in the provision of good care for 
people with dementia, not in research into medication
• When an instrument will be available to measure CAA in healthy 
people, then the results should be shared with family, colleagues, 
insurance and employers
• It is a good idea to have a CAA-screening program for healthy peo-
ple, for this will foster research into the natural development of the 
disease or into medication that serves the health of future patients
• Empty card
For the focusgroups with people with dementia we sim-
plified the card-game method, after consulting care-givers 
and social scientists with experience in focusgroups with 
people with dementia. They told us to limit the timeframe 
of the dialogue to max. 30–40 min and to avoid the stress 
that might be caused by having to read and choose between 
different cards. We decided therefore to skip the third con-
versation round on societal issues. In addition we offered 
not cards but a booklet as input for the conversation: on each 
page they would see only one possible future use at the time, 
and on the ‘values page’ we offered all personal values at 
once asking them to underline the values they considered 
most important. After each page we would ask participants 
to share their thoughts. During the conversation we wrote 
down a summary of what participants said on a white board, 
thus helping them to keep track of the conversation or to 
relate their input to things that had been previously said.
Data collection
In total we conducted seven focusgroups. Before we char-
acterize the participants of our focusgroups as ‘patients’ or 
‘non-patients’, it is however important to note that this dis-
tinction is not uncomplicated in this research. In fact, who 
counts as a ‘patient’ can shift as an effect of the develop-
ment of a new diagnostic method, such as the detection of 
CAA biomarkers in brain fluids which promises to enable 
diagnostics in pre-symptomatic phases. Some people may 
be ‘patients’ according to such a diagnosis, while not expe-
riencing complaints.
As we wanted to explore different perspectives to such a 
CAA-test, we therefore start to think about health and dis-
ease as extremes on a continuum. The participants in our 
focusgroups are positioned in different places on this contin-
uum: we did two focusgroups with people who received the 
diagnosis of dementia and experienced moderate to severe 
complaints (four and nine participants respectively). Two 
focusgroups with people who had intracerebral hemorrhage 
due to CAA and whose lives were marked by the effects of it 
(three participants each). In addition we did one focusgroup 
with people from the HCHWA-D group, some of whom had 
previously taken a genetic test to find out whether they have 
the inheritable form of CAA that runs in their families (six 
participants). Some of the participants in this HCHWA-D 
group (but not all) experienced mild to moderate complaints. 
In addition, we did one focusgroup with elderly people 
who considered themselves healthy (seven participants), 
while some of them did experience mild, but undiagnosed, 
memory losses; and one focusgroup with partners of people 
with dementia (seven participants) who had experienced no 
dementia complaints themselves. Finally, we conducted two 
individual interviews with people who had had intracerebral 
hemorrhage due to CAA. In the end we had to exclude one 
of the interviews since we were unable to complete it with 
this interviewee. In total we based the analysis on conversa-
tions with 40 people.
Participants were recruited in different ways. Elderly 
people were recruited by means of an advertisement in 
three supermarkets located in different neighborhoods 
in Nijmegen, a city in the east of the Netherlands; people 
with dementia as well as partners were recruited via two 
nursing homes in the middle and east of the Netherlands. 
We included people who suffered cerebral hemorrhages 
who consented to participating in the clinical trial of our 
project and asked them whether they would be willing to 
participate in a focusgroup too. HCHWA-D patients were 
recruited via the HCHWA-D patient organization. We were 
careful to select men (21) and women (18) from different 
socio-economic backgrounds and levels of education. We 
did not attract people from different ethnicities and cultural 
backgrounds.
In the case of people with dementia we conducted the 
focusgroups in the nursing home, as this was a safe and well-
known environment for them and would not cause stress. 
All other focusgroups were conducted either in a meeting 
room at a location that was convenient to the participants, 
in a nursing home, or at the university medical center. Two 
participants who had intracerebral hemorrhage were unable 
to read and were helped by the researcher (SvdB) during 
the focusgroup.
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Data analysis
The focusgroups have been recorded and transcribed ver-
batim. As we were interested to explore the meanings and 
values attached to (presymptomatic) CAA detection, we 
conducted the analysis using a grounded theory approach, 
in which the codes, themes and codebook emerge from the 
data (Glaser and Strauss 1967; Lingard et al. 2008; Tong 
et al. 2007). At first we analyzed the transcripts of the 
groups of participants separately, as we thought this would 
give insight into how their diverse personal experiences 
with the disease (or lack thereof) would reveal different 
meanings and values related to CAA biomarker research. 
There was, however, a lot of overlap in the ways people 
understood and valued CAA detection. In the second 
round, we therefore chose to analyze all groups together 
and focus on commonalities and differences in the val-
ues and meanings that arise from them. In the first round 
we linked passages in the transcripts to codes, such as : 
“knowing is accepting”, “knowing makes less uncertain”, 
“knowing causes fear”, “caring for family”, “insecure 
social relationships”, “preparing for the future”, “prepar-
ing for death”, “contribute to the health of future genera-
tions”. Subsequently we ordered the codes under themes, 
which allowed to acquire insight in their ways of reflecting 
on the meaning and value of CAA biomarker research. We 
chose themes such as knowing the cause of complains, 
“adapting one’s life” and “timing of the diagnosis”. As 
we saw that participants in the various groups attached 
different meanings and values to the future use of CAA-
biomarker detection in their own personal lives as opposed 
as how they would reflect on this in their relationships to 
family and friends, or with respect to society, we chose 
to order the presentation of the results accordingly. We 
presented these ways of reflecting graphically in Fig. 1.
In the following we will order our presentation of the 
results of our focusgroups and interview according to these 
three levels of understanding and valuing.
Results
Personal life
Respondents primarily reflected on the value of a diagnosis 
at a personal level. A diagnosis was considered important to 
know the cause of complaints and adapt future plans to the 
prospect of disease-development. This line of thinking was 
pursued when considering the value of the future possibility 
of a presymptomatic diagnosis.
Knowing the cause of complaints
Having a diagnosis is considered valuable to get more clarity 
and certainty about the cause of complains. This view, which 
we encounted in the various focus groups, is well captured 
in the following quote from a woman who explains the value 
of a diagnosis for her:
Well, yes, then you understand why you forget things 
or fail to understand.
(people with dementia)
Respondents furthermore appreciate biomarkers as a way 
to distinguish between different causes of complaints; such 
as, to separate between dementia and a burnout, or to distin-
guish the type of stroke, either an infarct (caused by a blood 
clot for which antithrombotic treatment should be given) and 
a cerebral hemorrhage (caused by rupture of blood vessel 
in which case antithrombotic treatment should be avoided).
… I would say that it can probably help to have some-
thing that indicates quicker that it is not a burnout. We 
took measures, all kind of measures to diminish stress 
… but the complaints didn’t go away, for it wasn’t a 
burnout. (partners)
… I had a major cerebral hemorrhage (..) The doc-
tor immediately gave blood thinners. But afterwards 
we found out…in me the blood flow is too good. The 
blood thinners were dangerous for me… (intracerebral 
hemorrhage)
Values such as knowledge and control were considered 
important in this respect, as acquiring appropriate knowl-
edge about the causes of complaints is considered important 
to tailor an appropriate response to the disease and to obtain 
some measure of control.
Personal life
Relaonships 
with relaves 
and friends
Society
Fig. 1  Three levels of reflection and evaluation about the value of 
CAA biomarkers
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Adapting one’s life
Obtaining a diagnosis also marks the beginning of a process 
in which people have to adapt their life-plans and integrate 
the diagnosis into their self-perception and expectation for 
the future. This is often a process that is characterized by 
dealing with emotions such as anger and fear. The following 
quote provides an example:
…The diagnosis spoiled my life for a large part…My 
fear…My fear [is] that my life will end as my sister’s 
did. [the sister also had dementia] (people with demen-
tia)
Values such as acceptance, finding joy in things one can 
still do, trust and (religious) faith, play a prominent role in 
how participants think they should deal with the diagnosis. 
But doing this is often considered difficult:
It [the diagnosis] is not something that makes you 
happy, but if you come as far as to accept and say ‘I’m 
going to try to make the best of it’ then you can give it 
a positive side. Well, that’s what I try at least. (people 
with dementia)
Some fear, yes yes…I think it is a kind of process. For 
me it lasted a year until I could give it a place [in my 
life]… I was very down for quite a while, but because 
of my trust and faith I came out of it. That is some-
thing I would like to give to everyone, but I can’t. It 
is something you can live with, I am personally con-
vinced of that. Enjoying the day… I am not a special 
human being: everyone can do that. You just have to 
accept that you have something that won’t go away … 
(HCHWA-D)
Timing of the diagnosis
Participants predominantly reject presymptomatic diagnos-
tics because (a) there is no appropriate therapeutic response 
available, and (b) it is not desirable to adapt one’s personal 
life prior to the experience of complaints. This is illustrated 
by the following quotes:
No. What can you do with it? You can do nothing with 
it. There is no cure… nothing… (people with demen-
tia)
If you know early that you are developing CAA, you 
could organize your life around it… That seems unde-
sirable, for it could mean that you close off your life 
before it is time… (partners)
Furthermore, some participants mention that obtaining 
a diagnosis presymptomatically might cause useless fear:
… how can you say you know what will happen? You 
can die of another disease… you are made scared of 
dementia and you die of cancer. Yes… that can hap-
pen, right? (people with dementia)
In the HCHWA-D focusgroup participants reflected exten-
sively on the value of presymptomatic diagnoses, as they had 
experience with it in their own lives. The value of an open 
future played a prominent role in their reflection:
…it robs you of your careless attitude towards the future 
… and that should not be the case when you’re twenty. 
(HCHWA-D)
The HCHWA-D patients argued that one should not adapt 
one’s life-plans to the disease too early in life, because it can 
influence decisions about life such as forming relationships, 
having children, or choosing a profession. It is for this reason 
that participants advised their children not to do it too early. 
In their own lives, however, some participants considered it 
important to have the presymptomatic diagnosis, as it helped 
them cope with the stress they experienced living in a family 
with HCHWA-D.
I am of the category, I am happy I had myself tested… 
I was already restless because it is in the family. And in 
this way [with the test] you at least have the possibility 
to rule it out. … So I said: I can rule it out if I don’t have 
it, and if the message goes in the other direction than 
that is a pity. But I cannot say that it makes me more 
stressed now that I know. I could not live very well with 
the uncertainty... (HCHWA-D)
Participants in the HCHWA-D group would not promote a 
presymptomatic diagnosis for people who do not have CAA in 
their families. Even within their own group they observe that 
the choice to be tested is highly personal, and they see less 
reason to test members of the healthy population.
… we have the inheritable form and even in our com-
munity people relate to it [the testing] differently. Some-
times even in the same family some people know, and 
others don’t. It is a sensitive matter… So, it is question-
able whether you should tell people who have nothing 
in their families … who have no bleedings [intracer-
ebral hemorrhages] and who do not have any cognitive 
problems. I think that is quite something…I think you 
shouldn’t do it. (HCHWA-D)
Relationships with relatives and friends
Our respondents made clear that obtaining a diagnosis marks 
the beginning of a process of change in relationships with rela-
tives and friends. This comes forwards in their communica-
tion habits, the responsibilities they adopt towards each other 
and in their shared future planning and—for some—in their 
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reflection about end of life decisions. Here we will focus on 
the last two aspects.
Adapting responsibilities
Once someone has dementia complaints, the division of 
tasks in the household often have to be revised. Participants 
in our focusgroups told many stories about how the adjust-
ment of mutual responsibilities can go wrong, which is often 
blamed on a tendency to deny the diagnosis on the part of 
the patients:
He denied it [the disease] for a long time. It is only 
since a few months that he will tell people at our farm, 
the veterinarian for example: would you write that 
down for me, for I cannot remember things very well 
anymore. Now that is since three, four, five months, 
although we know for sure what is wrong with his 
memory since eight years! (partners)
Others told stories about a relative’s denial of the decline 
of their capacities:
… and I told him [father] that I would not allow him 
to take my children in the car anymore. It was danger-
ous, really…but he once took them without telling me. 
I was furious… and he would say: I know what I am 
doing… I know it is hard to accept that you can’t do 
things you used to do… But, boy, I was so afraid… 
in the end I only brought my children over when my 
mother was around. (HCHWA-D)
Patients, on the other hand, provide insight into their per-
spective to the matter, sometimes understanding very clearly 
that they are not able to live up to the expectations of their 
loved ones:
…I keep fighting until I can repair my relationship, for 
it is fragile right now as my wife thinks I have changed. 
I can understand that. I have become very passive… in 
everything really, you know. I lack initiative. I sit qui-
etly in a chair at home and have nothing to do. I don’t 
mind that at all. And the whole room is full of dishes 
that need to be washed and my wife says: what do you 
think of that? Oh yes, that needs to be done…Nothing 
comes from me. I sit and I think it is OK. I don’t feel 
I miss anything either, you know. … Now sometimes 
she makes lists of things I should do that day. I don’t 
mind that. I do it all. (intracerebral hemorrhage)
Others tell that they think their relatives are too pushy to 
take over responsibilities, too patronizing, which is experi-
enced as stressful:
…They walk in like… I have this and that for you… 
I have lived alone for many years and do everything 
myself. They took my car at a certain moment and, 
no…I’d rather have that they didn’t know I have 
dementia. (people with dementia)
Stories such as these reveal a struggle between family 
members to find a new balance in their mutual division of 
responsibilities. In some cases participants also tell stories 
about situations in which they experience this balance:
I used to cook quite well. Sometimes I cooked for 
many people. That was no problem for me. I just did 
it liked this [she makes a juggling movement]. But now 
I can’t do that anymore. Now my husband does the 
cooking. And I help. I cut something, for example…it 
is nice to stand in the kitchen together. (intracerebral 
hemorrhage)
Planning the future
Patients as well as partners and healthy people mention 
valuing a diagnosis in order to be able to organize the right 
professional and informal care for the future. Sometimes, 
patients anticipate needing care themselves:
We arrived at a point where we wanted to change our 
life, so we decided not to have a big garden, big house, 
and to move to a place not too far from our family. A 
little more centralized and we did that because there is 
indication that I have Alzheimer. (people with demen-
tia)
Sometimes people anticipate needing care themselves, 
but also consider the needs of their relatives:
I think I will be all right in a nursing home and that 
my family should be able to live their own lives. … 
They didn’t choose this and my husband did not choose 
me knowing that I have this disease and if I myself 
would have known I had the disease then I probably 
would not have a relationship at all… I don’t know. 
(HCHWA-D)
Healthy elderly people and partners talk about providing 
care, but patients also often talk about themselves as people 
who care for their relatives; for example, by leaving them 
free to live their life, or trying to prepare everything as well 
as possible in case their capacities decline or they die:
I don’t know of course how this will continue…the 
development of my disease is unknown, for I don’t 
know when … when I will get a bleeding [intracerebral 
hemorrhage] again. But I want to leave things behind 
in a good way. … So I prepare everything. I organ-
ize my administration, so that my wife knows where 
she can find it …she will have enough on her mind… 
(intracerebral hemorrhage)
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Organizing care facilities for the diseased in such a way 
that family members will be able to continue living as good 
as possible is a recurrent theme in all of the focusgroups. 
Obtaining a diagnosis is important for it marks the beginning 
of preparatory activities to care well for each other. Obtain-
ing a diagnosis too early is not appreciated in this respect, 
for it would urge people to take preparatory measures at a 
moment when this is not yet necessary.
Timing of end of life decisions
Having a diagnosis early (presymptomatically), or being 
able to monitor the stage of development of the disease, is 
appreciated by some respondents, as it informs decisions 
about the best time to ask for euthanasia. As euthanasia is an 
accepted practice in the Netherlands, some patients reflected 
on the difficulty of picking the right time for it. This can be 
problematic for people with declining cognitive capacities, 
for the Dutch law requires patients who request euthanasia 
to be able to make an autonomous decision. The participant 
we interviewed anticipated that a presymptomatic diagnosis, 
or a tool that could monitor the progression of the disease 
prior to experiencing its symptoms, could help to make the 
decision at the right time:
I do not want to come so far as I don’t…don’t know 
what I do anymore… that my wife has to take me to a 
nursing home, for example. I had a beautiful life and I 
don’t want… don’t want to end up all strange. I talked 
about it [euthanasia] with my family doctor… a few 
times already, but she doesn’t want…yes, what is the 
right time? I want to prevent that I deteriorate and can’t 
ask for it anymore. So if there would be a way to see 
how far I am in the disease, this would be helpful for 
that, yes. (intracerebral hemorrhage, interview)
In the HCHWA-D focusgroup choosing the right time to 
graciously close off life was also a recurrent theme, although 
euthanasia was not mentioned. Some of the participants had 
themselves tested and know they have inherited the genetic 
variant that causes the disease. During the focusgroups they 
expressed that they go through periods of extreme stress 
when relatives suddenly die or rapidly develop cognitive 
deterioration. Stress causes sometimes complaints very simi-
lar to dementia, which causes even more worries. It is for 
this reason that they would value having a more objective 
instrument that can tell them the cause of their complaints, 
like a monitoring tool that can tell them how far the disease 
has progressed and allows them to take measures in time.
… now it is common in the hospital to say ‘you have 
the gene but we cannot do anything with it, so please 
come back some time.’ Now I think that for some 
people, that is fine, but if you…I experienced that I 
started misunderstanding things…like I was already 
in the middle of the disease process… while I was 
actually suffering a burn-out… and then you don’t 
know how to understand it. Then I found it very 
important to be monitored in order to know: should 
I be concerned, should I take measures? … I am a 
psychiatrist in a practice… If I know that I am far in 
the process, then I would stop. (HCHWA-D)
In the lives of people with HCHWA-D having a way of 
monitoring their disease progression allows them to act 
responsibly and not engage in work that they can no longer 
do. Another reason for patients with HCHWA-D to want 
to use biomarker information for monitoring is that this 
would allow medical specialists to tell them when their 
condition is deteriorating, rather than burdening their own 
family with it.
Imagine you are more affected than you yourself 
think… It can happen that you don’t see things your-
self. I, for example, told my husband that if I start 
doing strange things, I want you to tell me. You also 
see it in the patient association: some people—if I may 
say so—have a high opinion of themselves. Then it is 
valuable to have something objective … In a relation-
ship you spare each other … For that reason I would 
value having an objective measure that can tell me: 
how am I doing? (HCHWA-D)
Participants in all other focusgroups were however not so 
much interested in a monitoring function of the biomarker-
detection method. To some it was considered a frightening 
option to be able to follow your own degeneration, while not 
being able to stop it. The chance to make informed choices 
about when to stop working or start to close off life does 
not figure in all participant’s minds, and some consider it 
a frightening combination with euthanasia as they think 
presymptomatic diagnostics might lead to even less soci-
etal acceptance of dementia and an implicit societal push to 
choose euthanasia.
Woman: I think you will get more euthanasia. [when 
you get a diagnosis early. SvdB]
Researcher: more euthanasia?
Woman: Yes, more euthanasia.
Researcher: Why more euthanasia?
Woman: The word dementia means clean up and put 
in the corner. (people with dementia)
I would probably choose euthanasia myself… I don’t 
know. But I also think… well…if you live in a coun-
try where euthanasia is allowed, and you give people 
information that they have dementia early on… well 
what can you do with that information? I’m afraid peo-
ple will probably think they have to choose euthanasia, 
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as if it is the only reason… why they get this informa-
tion. I think that would be wrong. People should not 
feel they have to do something like that. (partners)
Societal aspects
Participants also reflected on the value of biomarker diag-
nostics for society. The issue they chose to talk about most 
was the issue concerning what society should primarily 
invest in: (1) in the provision of good care for people; or 
(2) into the development of medication. Sometimes the 
respondents looked at this issue as if it asked for an evalu-
ation of science itself, which they valued for the sake of 
itself:
I am in favour of science. Period. Yes, I am like that. I 
am a curious person. (Interview patient with intracer-
ebral hemorrhage)
But many participants reflected more specifically on the 
kinds of benefits they expected from scientific research, and 
how they would be able to use that to care for people. They 
consider it beneficial, for example, to have more informa-
tion about the disease, including its various complaints and 
stages. This allows people to prepare, as they know better 
what to expect:
(..) it [science] allows to observe the development of 
the disease …This helps to understand the disease and 
tell people about it when they get it. (healthy elderly 
people)
Or some actually looked at the value of follow-up 
research into the effectiveness of medication, which makes 
patients and their care-givers less helpless. For this purpose, 
some consider it valuable to do research on people, even if 
they do not yet have symptoms. That may help to prevent 
irreversible damage from occurring:
I think that if you do research in people who do not 
have symptoms yet, who stand at the beginning [of 
the disease], then maybe it is possible to develop 
medicine… Because now…when someone has it…it 
is actually already too late. (partners)
A medicine, that’s what we hope for. Then you can 
precede such a bleeding [an intracerebral hemorrhage] 
and prevent damage. (intracerebral hemorrhage)
For the HCHWA-D group, the focus on research is espe-
cially important, as they contribute in that way to the health 
of future patients, including their own children. Participants 
in this group that is marked by a family history of disease, 
find it important to take part in research to be able to care 
for the future health of their children:
Research is very important and you can perceive in 
our group that people are willing to do a lot to realize 
that. Because we all want research to go fast for our 
offspring, so yes, research is important in our group 
… for our children, our grandchildren. (HCHWA-D)
All of these remarks reveal that participants think that 
more knowledge and medication will help to care better for 
future patients. But not all participants agree with this. Some 
participants expressed a basic feeling of distrust towards sci-
ence and scientists:
For whom are scientists working? I don’t know, I am 
probably seeing things too negative. But it is their 
work and they can obtain high prestige, they can earn 
money. Are they concerned with us, with patients and 
their families? I do not think so. (partners)
Other participants perceived a distinction between the 
search for cure and care. They thought that more money 
should be spent on caring for the people with dementia in 
society, rather than spending it on finding innovative medi-
cation. They were not convinced that knowledge would 
eventually lead to more care, and expect more from general 
supportive activities for patients.
I am quite skeptic… searching for medication… I 
also see good results when there is good support and 
accompaniment … then there is a lot less risk ... I think 
there should be much more attention for what you can 
do with good care. Society does not sufficiently recog-
nize this. (healthy elderly people)
I know that it can have an enormous impact on your 
life when you become the guardian of your father or 
mother. We became ill ourselves, my brother and I. I 
think this is not good. It is not good that in the Nether-
lands we now burden informal care-givers even more. 
I think, come on boys in the government, please work 
behind that front door for a while and then you will 
talk differently. It is really important to give care-
givers some air, to let them live a little bit… (healthy 
elderly people)
Pondering on whether societal money should be spent on 
science or on better caring facilities, especially the groups 
with healthy elderly people and the partners reflected on 
the appropriate attitude that should be adopted and fostered 
towards diseases of old age in society:
… I think, how should I say this, yes you can spend a 
lot of money to get to know everything, but the ques-
tion is whether … that is worthwhile… You have to 
accept that there are things in life that happen and that 
you cannot influence. Let’s just put it like that. (part-
ners)
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In all of these answers, care seems to play a prominent 
role. Advancing knowledge is valued by some participants 
in our focusgroups as a way to strengthen capacities to care 
for patients. But other participants value acceptance of the 
limitations of life and think this is a lesson to learn for soci-
ety at large. They think society should not understand the 
degeneration of capacities towards the end of life as signs of 
disease that can be cured, but as part of the natural life cycle. 
Seeing it like this would make caring for people with demen-
tia a more natural part of everyday life, and would help to 
see the need to develop caring capacities. If dementia is seen 
as an anomaly that demands to be ‘fixed’ with medicine, this 
does not inspire to train caring capacities which are needed 
when people grow old.
Discussion
Given the described results, we conclude that (future) 
patients do not only—and not primarily—value biomarker 
detection in relation to the possibility of future treatments 
for CAA related diseases. In the absence of treatment, (pre-
symptomatic) CAA detection or monitoring is valued to the 
extent that it helps people to care for themselves, for family 
and friends or for society. This is the case in circumstances 
in which it (a) explains experienced complaints, (b) allows 
to start a process of psychological acceptance and social 
adaptation to the expected degeneration, (c) contributes to 
dealing with anxieties (with respect to inheritable versions 
of dementia), (d) informs adequately about when to start 
preparing for the end of life, (d) informs the planning of 
a request for euthanasia, or (e) allows society to deal with 
a growing number of dementia patients. CAA detection 
or monitoring is valued only when it enables people to do 
something with the results in their (self) care; it is not valued 
when the recipients of disease information feel unable to do 
anything with that information in their care, or if they do not 
feel cared for. In this case information about disease can be 
considered ‘premature’ and ‘harmful’ as they may feel the 
disease obliges them to anticipate the end of their lives while 
they do not know how.
Our results offer a contribution to the scholarly debate 
about what the right approach is to the expected ris-
ing amount of dementia patients with which this article 
started. We described in the introduction of this article that 
social scientists and ethicists often defend a care response 
to the growing number of people suffering from cognitive 
decline, which they contrast with the cure response that 
they ascribe to biomedical researchers investigating the 
biomarkers responsible to the development of CAA. The 
results of our focusgroups, however, reveal that partici-
pants do not always see care and cure strategies as rivals. 
Instead of looking at biomarker research as a stepping 
stone towards research into the effectiveness of therapy, 
participants in our focusgroups tended to evaluate future 
use of biomarkers with respect to whether and how they 
expect it to enhance their capacity to (self) care: they look 
at whether it fosters their capacity to deal with experienced 
complaints, with emotions, with (unstable) relationships 
with others and determine whether and how it can help 
them to organize support when their capacities will decline 
or support them to make decisions about how to end life 
graciously. In other words, they value the future prospects 
of biomarker research with respect to how it helps them 
to care for themselves and others, even if treatment is (and 
stays) unavailable.
Our study therefore suggests that end-users have tendency 
to evaluate future CAA detection and monitoring from a 
care perspective. But care is not contrasted with cure. Care 
is understood very broadly, in the inclusive definition pro-
vided by care ethicists Joan Tronto and Berenice Fischer as 
‘(..) a species of activity that includes everything we do to 
maintain, contain, and repair our ‘world’ so that we can live 
in it as well as possible (..)’ (Tronto 1993, p. 103). Knowing 
that CAA is at present not an aspect of their world which 
can be repaired, as there is no ‘technological fix’ available 
at present, and it may not become available in the future, 
participants in our focusgroups evaluate future uses of CAA 
biomarker detection for its imagined capacities to empower 
them to deal with CAA with resilience in their personal 
lives. While their personal lives and relationships differ as 
well as their personal history with CAA -which is visible 
in their varied evaluations- they have in common that they 
evaluate CAA diagnostics with respect to how it can support 
them to care for themselves and their family and friends. If 
treatment would become available in the future, this will be 
evaluated too for its influence on their capacity to care. Care 
and cure are therefore not opposed; rather, cure is one of the 
elements that contributes to care. If it would be possible to 
develop treatment, it would likely be evaluated according to 
its capacity to diminish or postpone complaints of disease 
and help people to maintain or repair their worlds.
This care perspective is also recognizable when they con-
sider the societal value of this type of research. While par-
ticipants disagree as to whether it is possible, or valuable, to 
do research into a cure, they have in common that they use a 
care-vocabulary in their evaluation. Some participants con-
sider finding a cure a way to improve care for future genera-
tions of patients, others consider it more caring to improve 
supportive facilities in order to make sure that society can 
maintain a good quality of life for the growing amount of 
people suffering from cognitive decline. While they are in 
disagreement about the value of finding a treatment, they 
do not oppose care to cure in their societal evaluations care.
While it is innovative to explore the meanings and values 
attached to innovative CAA detection in brain fluids, the 
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results of our study also has a lot in common with other qual-
itative studies exploring how Alzheimer patients and their 
informal caregivers experience diagnoses offered by cur-
rent diagnostic methods (Bunn et al. 2012; Spreadbury and 
Kipps 2017; Robinson et al. 2011; Greenwood and Smith 
2016). These studies also describe that respondents think 
that a diagnosis (a) helps to understand the cause of com-
plaints, (b) impacts on identity, roles and relationships, (c) 
contributes to a better understanding between patients and 
their relatives, (d) allows caregivers to adjust to increased 
responsibilities and become the main decision-maker, (e) 
to organize care and support in the present and towards the 
future, and (f) develop strategies to support or minimize the 
impact of dementia. As these studies focused on personal 
experiences with current Alzheimer diagnostics, they did not 
include a reflection on future ways to diagnose the disease, 
nor on the value of changing diagnostics. Furthermore, they 
did not look at the connection between these elements in a 
care approach. This is what our study adds.
The care perspective we identified in the responses of 
our respondents suggests, in our view, an interesting new 
way to look at the value of CAA biomarker research. This 
research bears not only the promise of finding a ‘techno-
logical fix’ for dementia, as authors such as Jongsma and 
Sand suggest in their article in Medicine Healthcare and 
Philosophy. The (presymptomatic) detection or monitoring 
of CAA biomarkers can also be valued for its capacity to 
foster capacities to (self) care. Research into CAA detection 
or monitoring should therefore not solely be understood and 
valued as a stepping stone towards follow-up research into 
innovative medicine. While medicine could contribute to 
(self)care, it is not sure whether and when it will be realized. 
This will depend on extensive research during the coming 
decades. In the meanwhile, it is important to anticipate the 
benefits and harms that will result if the promise of finding 
a treatment will not materialize. Therefore, it should also be 
assessed carefully how the availability of a CAA detection 
and monitoring method can foster capacities of patients and 
their care-givers to care for themselves and each other, and 
how it is able to undermine that capacity, in the absence 
of treatment. We think our study provides input to make 
such an assessment, which depends on the contribution it is 
able to offer to ‘good (self) care’ in different circumstances 
and to different people.
Our study suggests that information about disease is con-
sidered ‘harmful’ or ‘premature’ when recipients feel unable 
to act on that information in their (self-)care. In these situ-
ations recipients of information about CAA building up in 
their brain fluids may think that this obliges them to antici-
pate the end of their lives, while they are unsure who or what 
will help them to do that. This is our reason to think that it 
would be good to study whether and how CAA detection 
can be embedded fruitfully in palliative care. If palliative 
care is understood in a broad sense, such as the World 
Health Organization recommends, it starts when patients 
receive a diagnosis of an incurable disease and it may last 
for years. Furthermore, palliative care adopts a broad per-
spective to care, which takes into account the entire person 
of the patient, including physical, psychosocial and spiritual 
needs. Palliative care could therefore help to prevent the 
harm caused by a ‘premature’ diagnosis, by offering support 
to deal with this knowledge and integrate it in one’s personal 
life, as well as relationships with others.
Palliative care could support patients to deal with early 
diagnoses based on biomarkers, but biomarker diagnostics 
can probably also foster palliative care. It is a recognized 
problem that physicians often start the conversation about 
palliative care too late, when patients are no longer able to 
express their wishes and needs. Described obstacles to shap-
ing a timely advance care plan are that physicians (a) find it 
difficult to cohere palliative care with their curative role as 
physicians, (b) are afraid to start talking with patients about 
palliative care as they fear patients or their families will be 
unwilling to talk about it, or (c) fail to recognize that patients 
are already in the palliative phase (Oliver et al. 2015; Kupeli 
et al. 2016; Voltz 2016). If physicians and patients don’t 
shape an advance care plan in time, patients will fail to 
receive support and care tailored to their values and wishes 
as they will not have had the chance to communicate about 
it. It would be worthwhile to investigate whether CAA bio-
marker research can contribute to solving this problem, and 
start a timely conversation about palliative care. It would 
respond to a well described need in palliative care to make 
an advance care plan in time and it coheres with the per-
ceived value of biomarker research as a way to contribute to 
self-care, care for relatives, care for their own end of life, and 
care for future generations that we encountered in our study.
Of course, the connection between CAA diagnostics and 
palliative care also raises difficulties, as people who receive 
information about CAA building up in their brain fluid may 
not be ready to consider themselves palliative patients and 
resist to talk about palliative care. This is a problem that 
requires more attention in future research, for when CAA 
diagnostics becomes available it can be expected that more 
people will receive their diagnosis earlier. Furthermore, in 
some contexts that allow euthanasia—such as the Nether-
lands or Belgium—early diagnoses can raise particular sen-
sitive issues. As our study suggests, (future) patients and 
their care-givers consider the value of (presymptomatic) 
CAA detection and monitoring also in relation to euthana-
sia. Obtaining an early diagnosis can be experienced as a 
help to ask for euthanasia timely, before the degeneration of 
the brain prevents making an autonomous choice (which is 
a prerequisite of euthanasia). For others, however, detecting 
CAA early may produce a feeling in some patients that they 
are somehow expected to choose euthanasia by their social 
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environment. It would be advisable, in our view, if future 
research and ethical debate develops an appropriate response 
to these feelings, by means of integration of CAA diag-
nostics in care that is tailored to the person of the patient. 
Person-centered care is the primary goal of palliative care. 
Exploring how to integrate CAA detection and monitoring in 
a palliative care trajectory, would, in our view, be therefore 
a promising direction for future research, which attends to 
(new) needs that early diagnostics can generate, and fits with 
the care-language that (future) patients already adopt.
Of course it needs to be noted at the very end that our 
study has limitations too. We did not include participants 
from different cultural backgrounds, which limits the input 
that we collected. This is definitely an omission that needs 
attention in further research in the future. Furthermore, we 
shaped the cards that enhanced reflection and discussion in 
the focusgroups based on interviews. These interviews were 
carried out with a limited group of researchers and patients, 
which may have led to limited the amount of topics that our 
cards included. Even though participants in the focusgroups 
were free to start talking about other topics, the choice of 
topics on the cards may have constrained the range of top-
ics that was discussed. What is missing, for example, was a 
discussion of scenarios about possible misuse of information 
after a CAA biomarker test, or questions concerning how 
patients’ data should be handled. Future research in this area 
could include these topics as well.
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